Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2013, and company highlights.
“This quarter we continued to execute on our ‘Alnylam 5x15’ product strategy, where we are advancing RNAi therapeutics toward genetically defined targets for diseases with limited treatment options for patients and their caregivers.
Help employers find you! Check out all the jobs and post your resume.
